Jenny Pan-Yun Ting
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Recognitions
Jenny Pan-Yun Ting has a total of 757 co-authors. Here are the top co-authors by number of shared publications:
W. June Brickey
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, USA
12 shared publicationsHaitao Wen
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
11 shared publicationsWei-Chun Chou
Lineberger Comprehensive Cancer Center, University of North Carolina
11 shared publications- Meng Deng
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, USA
10 shared publications Haitao Guo
Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
9 shared publications- Kaixin Liang
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, USA
9 shared publications
Latest Publications
- Open Access
Folate metabolism in tumor-associated macrophages drives immunosuppressive function to promote tumor growth
Tumor-associated macrophages (TAMs) promote tumor progression, inhibit anti-tumor immunity, and induce resistance to immune checkpoint inhibitors (ICI). Metabolism is a primary determinant of TAM polarization, suggesting therapies that selectively modulate TAM metabolic state may hold therapeutic benefit. Here we demonstrate folate uptake and metabolism sustained by the myeloid-restricted folate receptor beta (FRβ) are critical for TAM immunosuppressive function. Folate was depleted in the microenvironment of human melanomas, suggesting FRβ upregulation by TAMs may be an adaptive response to folate scarcity. FRβ⁺ TAMs exhibited an immunosuppressive phenotype and were associated with immunotherapy resistance in melanoma patients. Genetic ablation of FRβ attenuated tumor growth across multiple cancer models and repolarized macrophages toward pro-inflammatory states, promoting tumor infiltration by activated lymphocytes. Critically, excess folate reversed the phenotypes observed with FRβ loss, suggesting these effects stem from impaired folate uptake by TAMs rather than a folate-independent role for FRβ. Integrated metabolomic, transcriptomic, and functional mechanistic studies demonstrated that folate acquisition via FRβ was required to generate reduced glutathione to limit mitochondrial reactive oxygen species (ROS) production. In the absence of FRβ, mitochondrial oxidative stress promoted canonical NF-kB signaling and macrophage pro-inflammatory polarization. Thus, FRβ couples a nutrient-limited microenvironment to TAM immunosuppressive function and represents a therapeutically tractable metabolic checkpoint for TAMs.
Open AccessFolate metabolism in tumor-associated macrophages drives immunosuppressive function to promote tumor growth
Tumor-associated macrophages (TAMs) promote tumor progression, inhibit anti-tumor immunity, and induce resistance to immune checkpoint inhibitors (ICI). Metabolism is a primary determinant of TAM polarization, suggesting therapies that selectively modulate TAM metabolic state may hold therapeutic benefit. Here we demonstrate folate uptake and metabolism sustained by the myeloid-restricted folate receptor beta (FRβ) are critical for TAM immunosuppressive function. Folate was depleted in the microenvironment of human melanomas, suggesting FRβ upregulation by TAMs may be an adaptive response to folate scarcity. FRβ⁺ TAMs exhibited an immunosuppressive phenotype and were associated with immunotherapy resistance in melanoma patients. Genetic ablation of FRβ attenuated tumor growth across multiple cancer models and repolarized macrophages toward pro-inflammatory states, promoting tumor infiltration by activated lymphocytes. Critically, excess folate reversed the phenotypes observed with FRβ loss, suggesting these effects stem from impaired folate uptake by TAMs rather than a folate-independent role for FRβ. Integrated metabolomic, transcriptomic, and functional mechanistic studies demonstrated that folate acquisition via FRβ was required to generate reduced glutathione to limit mitochondrial reactive oxygen species (ROS) production. In the absence of FRβ, mitochondrial oxidative stress promoted canonical NF-kB signaling and macrophage pro-inflammatory polarization. Thus, FRβ couples a nutrient-limited microenvironment to TAM immunosuppressive function and represents a therapeutically tractable metabolic checkpoint for TAMs.
- Open Access
- 7 August 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (32)
T cell–intrinsic AIM2 exacerbates lung inflammation in OVA-LPS- and HDM-induced asthma models
Asthma is a heterogeneous inflammatory airway disease characterized by immune dysregulation, airway hyperresponsiveness (AHR), and excessive immune activation. Although NLRP3 (NOD-like receptor family pyrin domain-containing 3) has been extensively studied in asthma, its role remains controversial, and the contribution of DNA sensor AIM2 (Absent in Melanoma 2) is less well defined. To assess AIM2’s relevance in asthma, we analyzed public human datasets and found increased AIM2 , but not NLRP3 , expression in severe asthma and in neutrophilic compared with paucigranulocytic asthma. In allergic asthma models induced by ovalbumin (OVA)-lipopolysaccharide (LPS) or house dust mite (HDM), AIM2 expression was increased in lung homogenates and bronchoalveolar lavage fluid cells. Analysis of a published single-cell RNA-seq dataset from the HDM model further showed increased Aim2 , but not Nlrp3 , expression in T helper cells, with most Aim2 -expressing cells coexpressing Gata3 . In the OVA-LPS model, whole-body Aim2 deficiency reduced AHR, inflammatory cytokine production, airway smooth muscle actin, and γH2A.X, consistent with decreased airway remodeling and tissue stress. Unexpectedly, CD4-specific, but not Treg- or myeloid-specific, Aim2 deletion significantly attenuated disease, identifying AIM2 in CD4 + T cells as a major driver of pathogenesis. In the HDM model, Aim2 deficiency similarly reduced AHR. Cell-specific deletion showed that AIM2 in CD4 + T cells promotes AHR and cytokine production, whereas AIM2 in myeloid cells modulates IgG1, IL-13-producing CD4 + T cells, and alveolar macrophages. These findings identify AIM2 as a regulator of allergic asthma acting predominantly through T cells, with an additional context-dependent contribution from myeloid cells.
- 7 August 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (32)
Open AccessT cell–intrinsic AIM2 exacerbates lung inflammation in OVA-LPS- and HDM-induced asthma models
Asthma is a heterogeneous inflammatory airway disease characterized by immune dysregulation, airway hyperresponsiveness (AHR), and excessive immune activation. Although NLRP3 (NOD-like receptor family pyrin domain-containing 3) has been extensively studied in asthma, its role remains controversial, and the contribution of DNA sensor AIM2 (Absent in Melanoma 2) is less well defined. To assess AIM2’s relevance in asthma, we analyzed public human datasets and found increased AIM2 , but not NLRP3 , expression in severe asthma and in neutrophilic compared with paucigranulocytic asthma. In allergic asthma models induced by ovalbumin (OVA)-lipopolysaccharide (LPS) or house dust mite (HDM), AIM2 expression was increased in lung homogenates and bronchoalveolar lavage fluid cells. Analysis of a published single-cell RNA-seq dataset from the HDM model further showed increased Aim2 , but not Nlrp3 , expression in T helper cells, with most Aim2 -expressing cells coexpressing Gata3 . In the OVA-LPS model, whole-body Aim2 deficiency reduced AHR, inflammatory cytokine production, airway smooth muscle actin, and γH2A.X, consistent with decreased airway remodeling and tissue stress. Unexpectedly, CD4-specific, but not Treg- or myeloid-specific, Aim2 deletion significantly attenuated disease, identifying AIM2 in CD4 + T cells as a major driver of pathogenesis. In the HDM model, Aim2 deficiency similarly reduced AHR. Cell-specific deletion showed that AIM2 in CD4 + T cells promotes AHR and cytokine production, whereas AIM2 in myeloid cells modulates IgG1, IL-13-producing CD4 + T cells, and alveolar macrophages. These findings identify AIM2 as a regulator of allergic asthma acting predominantly through T cells, with an additional context-dependent contribution from myeloid cells.
- Open Access
- 19 November 2025
- Published by Springer Nature in Nature
- Vol. 648 (8092) , E4
Author Correction: AIM2 in regulatory T cells restrains autoimmune diseases
- 19 November 2025
- Published by Springer Nature in Nature
- Vol. 648 (8092) , E4
Open AccessAuthor Correction: AIM2 in regulatory T cells restrains autoimmune diseases
- Open Access
- 27 October 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (44)
Inflammasome targeting for periodontitis prevention is sex dependent
Inflammasome initiates inflammation via the maturation of interleukin-1 beta (IL-1β). Periodontitis is a prevalent, male-biased disease characterized by inflammation-driven bone loss, yet the mechanism(s) of this sex bias is unknown. This study explored whether enhanced inflammasome represents a causal mechanism for this bias. Analyses of three separate human studies (>6,200 samples) show that males have significantly higher IL-1β in the gingival crevicular fluid than females during health and periodontitis. This pattern is experimentally reproduced with different versions of the ligature-induced periodontitis mouse model where males show greater IL-1β secretion than females. The inflammasome drives bone resorption in males but not females as revealed by analyses of inflammasome gene-deletion mice. Pharmacologic treatment with a caspase-1/4 inhibitor reduces inflammatory cell infiltration, dampens osteoclastogenesis signaling (via the receptor activator of nuclear factor-kappa B pathway), and prevents bone resorption in males but not females during experimental periodontitis. While ovariectomized females show no change in their nonresponsiveness to caspase-1/4 inhibition, orchiectomized males no longer respond to the inhibition, suggesting the importance of an intact male reproductive system in the mediation of this inhibition. Thus, our study identifies inflammasome activation as causal for male-biased experimental periodontitis and supports sex-stratified studies to foster future advancement of inflammasome therapeutics in periodontics.
- 27 October 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (44)
Open AccessInflammasome targeting for periodontitis prevention is sex dependent
Inflammasome initiates inflammation via the maturation of interleukin-1 beta (IL-1β). Periodontitis is a prevalent, male-biased disease characterized by inflammation-driven bone loss, yet the mechanism(s) of this sex bias is unknown. This study explored whether enhanced inflammasome represents a causal mechanism for this bias. Analyses of three separate human studies (>6,200 samples) show that males have significantly higher IL-1β in the gingival crevicular fluid than females during health and periodontitis. This pattern is experimentally reproduced with different versions of the ligature-induced periodontitis mouse model where males show greater IL-1β secretion than females. The inflammasome drives bone resorption in males but not females as revealed by analyses of inflammasome gene-deletion mice. Pharmacologic treatment with a caspase-1/4 inhibitor reduces inflammatory cell infiltration, dampens osteoclastogenesis signaling (via the receptor activator of nuclear factor-kappa B pathway), and prevents bone resorption in males but not females during experimental periodontitis. While ovariectomized females show no change in their nonresponsiveness to caspase-1/4 inhibition, orchiectomized males no longer respond to the inhibition, suggesting the importance of an intact male reproductive system in the mediation of this inhibition. Thus, our study identifies inflammasome activation as causal for male-biased experimental periodontitis and supports sex-stratified studies to foster future advancement of inflammasome therapeutics in periodontics.
- 19 September 2025
- Published by Springer Nature in Nature Immunology
- Vol. 26 (11) , 1916-1930
STING signals to NF-κB from late endolysosomal compartments using IRF3 as an adaptor
NF-κB is central for activation of immune responses. Cytosolic DNA activates the cGAS–STING pathway to induce type I interferons (IFNs) and signaling through NF-κB, thus instigating host defenses and pathological inflammation. However, the mechanism underlying STING-induced NF-κB activation is unknown. Here we report that STING activates NF-κB in a delayed manner, following exit from the Golgi to endolysosomal compartments. Activation of NF-κB is dependent on the IFN-inducing transcription factor IRF3 but is independent of type I IFN signaling. This activation pattern is evolutionarily conserved in tetrapods. Mechanistically, the monomer IRF3 is recruited to STING pS358, with delayed kinetics relative to IRF3 recruitment to STING pS366, which promotes type I IFN responses. IRF3 engagement with STING pS358 induces trafficking to late endolysosomal compartments, supporting recruitment of TRAF6 and activation of NF-κB. We identify a TRAF6 binding motif in IRF3 that facilitates recruitment of TRAF6. This work defines a signaling surface on STING and a function for IRF3 as an adaptor in immune signaling. These findings indicate that STING signaling to NF-κB is enabled only within a short time window between exit from the Golgi and lysosomal degradation, possibly limiting inflammation under homeostatic and danger-sensing conditions.
- 19 September 2025
- Published by Springer Nature in Nature Immunology
- Vol. 26 (11) , 1916-1930
STING signals to NF-κB from late endolysosomal compartments using IRF3 as an adaptor
NF-κB is central for activation of immune responses. Cytosolic DNA activates the cGAS–STING pathway to induce type I interferons (IFNs) and signaling through NF-κB, thus instigating host defenses and pathological inflammation. However, the mechanism underlying STING-induced NF-κB activation is unknown. Here we report that STING activates NF-κB in a delayed manner, following exit from the Golgi to endolysosomal compartments. Activation of NF-κB is dependent on the IFN-inducing transcription factor IRF3 but is independent of type I IFN signaling. This activation pattern is evolutionarily conserved in tetrapods. Mechanistically, the monomer IRF3 is recruited to STING pS358, with delayed kinetics relative to IRF3 recruitment to STING pS366, which promotes type I IFN responses. IRF3 engagement with STING pS358 induces trafficking to late endolysosomal compartments, supporting recruitment of TRAF6 and activation of NF-κB. We identify a TRAF6 binding motif in IRF3 that facilitates recruitment of TRAF6. This work defines a signaling surface on STING and a function for IRF3 as an adaptor in immune signaling. These findings indicate that STING signaling to NF-κB is enabled only within a short time window between exit from the Golgi and lysosomal degradation, possibly limiting inflammation under homeostatic and danger-sensing conditions.
- Open Access
T cell AIM2 Exacerbates Lung Inflammation in OVA-LPS and HDM-induced Asthma Models
Asthma is a complex airway inflammatory disease characterized by immune dysregulation, with diverse cellular contributors to inflammation that result in airway hyperresponsiveness (AHR) and excessive immune responses. The role of the inflammasome in asthma is conflicted. AIM2 is an innate immune receptor that activates the inflammasome through DNA binding. The clinical relevance of AIM2 in asthma is supported by analysis of blood or endobronchial biopsies from patients with severe asthma, showing increased AIM2 but not NLRP3 expression. We investigated the role of AIM2 in allergic asthma using ovalbumin (OVA)-LPS and house dust mite (HDM)-induced models. AIM2 expression was elevated in lung homogenates and bronchoalveolar lavage fluid (BALF) cells from allergen-induced groups compared to controls. In the OVA-LPS model, deletion of Aim2 led to reduced airway smooth muscle actin expression and DNA damage, contributing to decreased AHR and lung inflammation in whole body Aim2−/− mice. Surprisingly, cell-specific deletion in CD4+ T cells but not regulatory T cells or myeloid cells significantly affected AHR, indicating AIM2 in CD4+ T cells is a main driver of pathogenesis. Additionally, in HDM-induced asthma, Aim2−/− mice also exhibited reduced AHR. Cell-specific deletion reveals that AIM2 in CD4+ T cells promotes AHR and cytokine production, while AIM2 in myeloid cells modulates IgG1 levels and IL-13-producing CD4+ T cells, and the percentage of alveolar macrophages in BALF. These findings reveal that AIM2 differentially regulates HDM-induced allergic asthma through distinct exacerbating roles in T cells and myeloid cells, highlighting its potential as a therapeutic target.
Open AccessT cell AIM2 Exacerbates Lung Inflammation in OVA-LPS and HDM-induced Asthma Models
Asthma is a complex airway inflammatory disease characterized by immune dysregulation, with diverse cellular contributors to inflammation that result in airway hyperresponsiveness (AHR) and excessive immune responses. The role of the inflammasome in asthma is conflicted. AIM2 is an innate immune receptor that activates the inflammasome through DNA binding. The clinical relevance of AIM2 in asthma is supported by analysis of blood or endobronchial biopsies from patients with severe asthma, showing increased AIM2 but not NLRP3 expression. We investigated the role of AIM2 in allergic asthma using ovalbumin (OVA)-LPS and house dust mite (HDM)-induced models. AIM2 expression was elevated in lung homogenates and bronchoalveolar lavage fluid (BALF) cells from allergen-induced groups compared to controls. In the OVA-LPS model, deletion of Aim2 led to reduced airway smooth muscle actin expression and DNA damage, contributing to decreased AHR and lung inflammation in whole body Aim2−/− mice. Surprisingly, cell-specific deletion in CD4+ T cells but not regulatory T cells or myeloid cells significantly affected AHR, indicating AIM2 in CD4+ T cells is a main driver of pathogenesis. Additionally, in HDM-induced asthma, Aim2−/− mice also exhibited reduced AHR. Cell-specific deletion reveals that AIM2 in CD4+ T cells promotes AHR and cytokine production, while AIM2 in myeloid cells modulates IgG1 levels and IL-13-producing CD4+ T cells, and the percentage of alveolar macrophages in BALF. These findings reveal that AIM2 differentially regulates HDM-induced allergic asthma through distinct exacerbating roles in T cells and myeloid cells, highlighting its potential as a therapeutic target.
- Open Access
- 8 August 2024
- Published by Springer Nature in Nature Nanotechnology
- Vol. 19 (8) , 1235
Author Correction: Universal STING mimic boosts antitumour immunity via preferential activation of tumour control signalling pathways
- 8 August 2024
- Published by Springer Nature in Nature Nanotechnology
- Vol. 19 (8) , 1235
Open AccessAuthor Correction: Universal STING mimic boosts antitumour immunity via preferential activation of tumour control signalling pathways
- 12 July 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 9 (97) , eadn0178
Initiator cell death event induced by SARS-CoV-2 in the human airway epithelium
Virus-induced cell death is a key contributor to COVID-19 pathology. Cell death induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is well studied in myeloid cells but less in its primary host cell type, angiotensin-converting enzyme 2 (ACE2)–expressing human airway epithelia (HAE). SARS-CoV-2 induces apoptosis, necroptosis, and pyroptosis in HAE organotypic cultures. Single-cell and limiting-dilution analysis revealed that necroptosis is the primary cell death event in infected cells, whereas uninfected bystanders undergo apoptosis, and pyroptosis occurs later during infection. Mechanistically, necroptosis is induced by viral Z-RNA binding to Z-DNA–binding protein 1 (ZBP1) in HAE and lung tissues from patients with COVID-19. The Delta (B.1.617.2) variant, which causes more severe disease than Omicron (B1.1.529) in humans, is associated with orders of magnitude–greater Z-RNA/ZBP1 interactions, necroptosis, and disease severity in animal models. Thus, Delta induces robust ZBP1-mediated necroptosis and more disease severity.
- 12 July 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 9 (97) , eadn0178
Initiator cell death event induced by SARS-CoV-2 in the human airway epithelium
Virus-induced cell death is a key contributor to COVID-19 pathology. Cell death induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is well studied in myeloid cells but less in its primary host cell type, angiotensin-converting enzyme 2 (ACE2)–expressing human airway epithelia (HAE). SARS-CoV-2 induces apoptosis, necroptosis, and pyroptosis in HAE organotypic cultures. Single-cell and limiting-dilution analysis revealed that necroptosis is the primary cell death event in infected cells, whereas uninfected bystanders undergo apoptosis, and pyroptosis occurs later during infection. Mechanistically, necroptosis is induced by viral Z-RNA binding to Z-DNA–binding protein 1 (ZBP1) in HAE and lung tissues from patients with COVID-19. The Delta (B.1.617.2) variant, which causes more severe disease than Omicron (B1.1.529) in humans, is associated with orders of magnitude–greater Z-RNA/ZBP1 interactions, necroptosis, and disease severity in animal models. Thus, Delta induces robust ZBP1-mediated necroptosis and more disease severity.
- Top Cited Papers
- 13 March 2024
- Published by Springer Nature in Nature Nanotechnology
- Vol. 19 (6) , 856-866
Universal STING mimic boosts antitumour immunity via preferential activation of tumour control signalling pathways
The efficacy of STING (stimulator of interferon genes) agonists is due to various factors, primarily inefficient intracellular delivery, low/lack of endogenous STING expression in many tumours, and a complex balance between tumour control and progression. Here we report a universal STING mimic (uniSTING) based on a polymeric architecture. UniSTING activates STING signalling in a range of mouse and human cell types, independent of endogenous STING expression, and selectively stimulates tumour control IRF3/IFN-I pathways, but not tumour progression NF-κB pathways. Intratumoural or systemic injection of uniSTING-mRNA via lipid nanoparticles (LNPs) results in potent antitumour efficacy across established and advanced metastatic tumour models, including triple-negative breast cancer, lung cancer, melanoma and orthotopic/metastatic liver malignancies. Furthermore, uniSTING displays an effective antitumour response superior to 2′3′-cGAMP and ADU-S100. By favouring IRF3/IFN-I activity over the proinflammatory NF-κB signalling pathway, uniSTING promotes dendritic cell maturation and antigen-specific CD8+ T-cell responses. Extracellular vesicles released from uniSTING-treated tumour cells further sensitize dendritic cells via exosome-containing miRNAs that reduced the immunosuppressive Wnt2b, and a combination of LNP-uniSTING-mRNA with α-Wnt2b antibodies synergistically inhibits tumour growth and prolongs animal survival. Collectively, these results demonstrate the LNP-mediated delivery of uniSTING-mRNA as a strategy to overcome the current STING therapeutic barriers, particularly for the treatment of multiple cancer types in which STING is downregulated or absent.
- 13 March 2024
- Published by Springer Nature in Nature Nanotechnology
- Vol. 19 (6) , 856-866
Top Cited PapersUniversal STING mimic boosts antitumour immunity via preferential activation of tumour control signalling pathways
The efficacy of STING (stimulator of interferon genes) agonists is due to various factors, primarily inefficient intracellular delivery, low/lack of endogenous STING expression in many tumours, and a complex balance between tumour control and progression. Here we report a universal STING mimic (uniSTING) based on a polymeric architecture. UniSTING activates STING signalling in a range of mouse and human cell types, independent of endogenous STING expression, and selectively stimulates tumour control IRF3/IFN-I pathways, but not tumour progression NF-κB pathways. Intratumoural or systemic injection of uniSTING-mRNA via lipid nanoparticles (LNPs) results in potent antitumour efficacy across established and advanced metastatic tumour models, including triple-negative breast cancer, lung cancer, melanoma and orthotopic/metastatic liver malignancies. Furthermore, uniSTING displays an effective antitumour response superior to 2′3′-cGAMP and ADU-S100. By favouring IRF3/IFN-I activity over the proinflammatory NF-κB signalling pathway, uniSTING promotes dendritic cell maturation and antigen-specific CD8+ T-cell responses. Extracellular vesicles released from uniSTING-treated tumour cells further sensitize dendritic cells via exosome-containing miRNAs that reduced the immunosuppressive Wnt2b, and a combination of LNP-uniSTING-mRNA with α-Wnt2b antibodies synergistically inhibits tumour growth and prolongs animal survival. Collectively, these results demonstrate the LNP-mediated delivery of uniSTING-mRNA as a strategy to overcome the current STING therapeutic barriers, particularly for the treatment of multiple cancer types in which STING is downregulated or absent.